HeartBeam Inc. (NASDAQ: BEAT) has been highlighted as experiencing a significant turning point, according to a recent article discussing Joseph Gunnar & Co.’s upgrade of the company from Hold to Buy. The firm also raised its 12-month price target to $4 from $1, citing regulatory progress and the company’s transition toward commercialization. The upgrade follows the FDA clearance of HeartBeam’s 12-lead ECG synthesis software in December 2025 for arrhythmia assessment, which resolved an earlier regulatory setback and allowed HeartBeam to advance to commercial-stage status.
The report from Joseph Gunnar & Co. states, “We upgrade HeartBeam to a BUY and High-Risk rating with a raised price target of $4 (from $1), reflecting progress in cardiac risk detection.” This upgrade underscores the market’s positive reception to HeartBeam’s recent regulatory achievements and its potential in the cardiac care market. The company is developing the first cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions, a platform technology designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence.
HeartBeam aims to transform cardiac care by enabling physicians to identify cardiac health trends and acute conditions outside of medical facilities, thereby redefining cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to its technology. For more information about HeartBeam, visit www.HeartBeam.com.
The full article highlighting HeartBeam’s progress is available at https://ibn.fm/NrrYt. For the latest news and updates relating to BEAT, visit the company’s newsroom at https://ibn.fm/BEAT.
